TrovaGene Inc (NASDAQ:TROV) Strengthens Board With Appointment Of Dr. Athena Countouriotis

TrovaGene Inc (NASDAQ:TROV) reported the strengthening and expansion of its Board with the election of Athena Countouriotis, M.D., who brings extensive experience leading clinical advancement programs, from preclinical through clinical phases, and approval. During the course of her career, Dr. Countouriotis has been involved in numerous clinical plans, with a focus within oncology that have […]

pSivida Corp. (NASDAQ:PSDV) Elects Veteran Healthcare Executive To Its Board

pSivida Corp. (NASDAQ:PSDV) reported that it has elected Kristine Peterson, who is a seasoned healthcare executive, to its Board of Directors. Peterson has extensive pharma experience, having worked as the CEO of Valeritas from 2009 to 2016, a commercial-stage medical technology firm focused on simplifying life and improving health for people with diabetes. She has […]

Heat Biologics Inc (NASDAQ:HTBX) Appoints Dr. Jeff Hutchins As New Chief Operating Officer

Heat Biologics Inc (NASDAQ:HTBX) has appointed Dr. Jeff Hutchins as its Chief Operating Officer. Dr. Hutchins was previously CSO and SVP, Pre-clinical Development with the company. In his new role, he will lead product development initiatives for Heat Biologic and its Pelican Therapeutics subsidiary firm. The management view Jeff Wolf, the CEO of Heat Biologics, […]

Amgen, Inc. (NASDAQ:AMGN) Migraine Treatment Drug Passes Phase 2 Trials

In a breakthrough in migraine treatment, the Phase 2 results of the clinical trials of AMG 334 drug by Amgen, Inc. (NASDAQ:AMGN) has been successful. Competing with the existing migraine drugs, the monthly rates of migraine attacks were comparably less when using this medication. According to the company, the AMG 334 drug lowered the chance […]

Bristol-Myers Squibb Co (NYSE:BMY), AbbVie Inc (NYSE:ABBV) Developing Drug To Delay Growth of Myeloma Cancer

Bristol-Myers Squibb Co (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) are working in collaboration for a cancer therapy that can delay the progression of the myeloma cancer in less than five months. The company is currently in the final stages of the study and is now looking forward to seeking the approval from the U.S. Food and […]

Juno Therapeutics Inc (NASDAQ:JUNO) and AstraZeneca plc (ADR) (NYSE:AZN) Pair Up for new Cancer Therapy

Juno Therapeutics Inc (NASDAQ:JUNO) and AstraZeneca plc (ADR) (NYSE:AZN) are collaborating to test their respective cancer therapies in tandem. The collaboration will combine new-fangled therapies that will use the immune system to combat tumours. Under the deal, the duo will jointly fund a Phase I study that combines Juno’s CAR-T therapy and antibodies developed by […]

Keytruda By Merck & Co., Inc. (NYSE:MRK) Is More Effective Than Yervoy of Bristol-Myers Squibb Co (NYSE:BMY),

Merck & Co., Inc. (NYSE:MRK) will file for U.S regulatory approval for the purpose of making their drug Keytruda, marketable. The drug provides treatment for patients with lung cancer. Statistically speaking, people with lung cancer are more than those with melanoma. Moreover, Yervoy, a drug by the Bristol-Myers Squibb Co (NYSE:BMY), which treats melanoma has […]

Combining The Bristol-Myers Squibb Co (NYSE:BMY) Drugs Are Effective Against Melanoma

Philadelphia- The combination of two drugs, by Bristol-Myers Squibb Co (NYSE:BMY) proves to be effective in treating melanoma, than taking them individually. This was found by a study, which was reported on Monday. However, it could prove to be a costlier option for the patients, even though it is an effective one. The researchers were […]

Researchers of Bristol-Myers Squibb Co (NYSE:BMY) Make Available Data On Amino Acids

Bristol-Myers Squibb Co (NYSE:BMY)’s researchers have made available the data on amino acids. As per the reports, the information was first reported by one of the Life Science Weekly’s reporters. Insights On The Report: As per the information, carboxylic acid derivatives’ Pd-catalyzed beta-C-H functionalizations that use auxiliary as nothing else but the directing group have […]

Bristol-Myers Squibb Co (NYSE:BMY) To Make The Best Use of The Prevailing Growth Opportunities In Biopharma

Whenever the scientists come across any major discovery in the drug research and development, the biopharma industry witnesses a major change in the attitude of the leading market players. According to reports, the leading company Bristol-Myers Squibb Co (NYSE:BMY) is all set to follow the same path that others have followed in the past. Insights […]

Bristol-Myers Squibb Co (NYSE:BMY)’s Opdivo A Death Call For Chemotherapy

Boston, MA 09/29/2014 (wallstreetpr) – As per a Reuters report, Bristol-Myers Squibb Co (NYSE:BMY) has taken another shot to the success. The drug maker has achieved another important milestone with its immunotherapy drug, Opdivo. As per a new melanoma study, the drug had reported an increased and imporved response rate complemented by fewer side effects […]

Merck & Co., Inc. (NYSE:MRK) Sued For Using Patented Method In Developing Cancer Drug ‘Keytruda’

Boston, MA 09/09/2014 (wallstreetpr) – Bristol-Myers Squibb Co (NYSE:BMY), along with its partner ONO PHARMACEUTICAL CO., LTD., sued Merck & Co., Inc. (NYSE:MRK) for patent infringement. The matter concerns Merck’s newly launched drug, ‘Keytruda,’ which is aimed at treating the deadly skin cancer melanoma. As the drug received approval from the U.S. Food and Drug Administration on […]

Merck & Co., Inc. (NYSE:MRK) Dragged To Court On Immunotherapy Patent Issue

Boston, MA 09/08/2014 (wallstreetpr) – Global health care company Merck & Co., Inc. (NYSE:MRK) has been dragged to the court by biopharmaceutical company Bristol-Myers Squibb Co (NYSE:BMY) on the patent issue concerning the immunotherapy. Patent Issue Merck & Co., Inc. (NYSE:MRK) has been charged with infringing Bristol-Myers’ patent of immunotherapy, which is a system that makes […]

Merck & Co., Inc. (NYSE:MRK) Much Awaited Melanoma Treating Drug Gains FDA Approval

Boston, MA 09/05/2014 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK)’s tumor fighting drug, pembrolizumab, aimed at patients suffering from advanced melanoma and who failed to respond to other therapies, has received FDA approval. The Food and Drug Administration approved of Merck & Co., Inc. (NYSE:MRK)’s much-awaited drug for the treatment in an advanced stage of skin […]

Pfizer Inc. (NYSE:PFE) And Bristol-Myers Squibb Co (NYSE:BMY) Announced FDA Clearance For Eliquis For Blood Clots Treatment

Boston, MA 08/22/2214 (wallstreetpr) – Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co (NYSE:BMY) announced recently that the USFDA has given an extension of approving Eliquis, the blood thinner, which shall be used for the treatment of fatal blood clots. The treatment of two kinds of blood clots can be done by way of this blood […]